March 29th 2023
Adding avelumab to VEGFR inhibitor axitinib may prolong survival and improve outcomes among patients with recurrent/metastatic adenoid cystic carcinoma.
First-Line Tislelizumab Plus Chemotherapy Could Become SOC in Nasopharyngeal CancerApril 20th 2022
Investigators of the phase 3 RATIONALE-309 trial found an improvement in progression-free survival for patients with recurrent or metastatic nasopharyngeal cancer treated with tislelizumab plus chemotherapy vs chemotherapy alone.
Favorable Outcomes, Improved QOL Seen With Radiotherapy De-Escalation in HPV-Associated Oropharyngeal CarcinomaApril 1st 2022
Patients with human papillomavirus–associated oropharyngeal carcinoma who were given de-escalated doses of radiotherapy saw a better quality of life and favorable outcomes.
Maintenance Capecitabin Yields Significant PFS Improvement in Newly Diagnosed Nasopharyngeal CancerMarch 4th 2022
A significant progression-free survival benefit was observed with the use of capecitabine maintenance therapy in newly diagnosed nasopharyngeal carcinoma vs best supportive care.
Tisotumab Vedotin Yields Promising Preliminary Activity in SCCHNMarch 2nd 2022
Patients with squamous cell carcinoma of the head and neck who had progressive disease following treatment with platinum-based chemotherapy and a checkpoint inhibitor experienced promising safety and preliminary efficacy following treatment with tisotumab vedotin.
Circulating TTMV HPV Tumor DNA May Detect Recurrence of HPV-Driven Oropharyngeal CancersFebruary 25th 2022
Research presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium highlighted the potential to detect oropharyngeal cancer recurrence using circulating tumor tissue modified viral–human papillomavirus DNA.
Radiotherapy De-Escalation Improves Toxicity in p16+ Oropharyngeal Squamous Cell CarcinomaFebruary 25th 2022
A presentation from the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium showed a de-escalated radiotherapy dose to 54 Gy vs 70 Gy led to better measures of toxicity in those with p16+ oropharyngeal squamous cell carcinoma.
DART Meets Noninferiority PFS Benchmark in HPV-Related OPSCCFebruary 25th 2022
In a pre-planned pooled analysis of data from the MC1273 and MC1675 trials presented at the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium, de-escalated adjuvant radiation therapy met criteria for efficacy in human papillomavirus–related oropharyngeal squamous cell carcinoma.
PDS0101/Pembrolizumab Achieves Preliminary Objective Response End Point for Advanced Head and Neck CancerFebruary 7th 2022
PDS Biotechnology Corporation announced that the combination of PDS0101 and pembrolizumab achieved preliminary response efficacy for patients with advanced human papillomavirus–associated head and neck cancer.
Second-Line Abiraterone Plus Hormone Agonist Is a Viable Option for AR+ Castration-Resistant Salivary Gland CancerFebruary 3rd 2022
Abiraterone acetate and luteinizing hormone–releasing hormone agonist is a promising second-line option for androgen receptor–expressing castration resistant salivary gland cancer.
Non-Hispanic Black Patients With Head and Neck Cancer May Have Significantly Worse Survival vs Other Minority GroupsJanuary 6th 2022
Research indicated that non-Hispanic Black patients had significantly worse 5-year overall survival outcomes compared with Hispanic, Asian/Pacific Islander, and American Indian/Alaska Native patients.
Close/Positive Surgical Margins in Salivary Gland Cancer Linked With Poor Outcomes, But Low-Risk Disease May Be WatchedDecember 23rd 2021
Although findings suggest that close or positive surgical margins are associated with a higher risk of poor outcomes in salivary gland cancer, it did not appear to be an independent factor for poor outcomes after adjusting for tumor stage, histologic risk group, and adjuvant radiotherapy use.
Lifileucel Plus Pembrolizumab Yields Positive ORR in Advanced CancersNovember 16th 2021
Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.
Individuals With HPV-Positive Oropharynx Cancer Likely to Have Pathologic ENE, Positive Margins Following TORSNovember 9th 2021
Patients who received transoral robotic surgery for human papillomavirus–positive oropharynx squamous cell carcinoma were likely to experience pathologic extra nodal extension and positive margins following surgery.
DART Yields Robust Survival Benefit vs Standard of Care in HPV-Associated Oropharyngeal Squamous Cell CarcinomaOctober 28th 2021
Patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma experienced good quality of life and promising survival benefit after being treated with de-escalated adjuvant radiation therapy.
Primary Radiotherapy as De-Escalation Strategy Yields Efficacious Survival Outcomes in HPV-Associated Oropharyngeal Squamous Cell CarcinomaOctober 27th 2021
Patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma experienced efficacious survival benefits from treatment with primary radiotherapy.
EC-18 Yields Positive Results for Chemoradiation-Induced Oral Mucositis in Head and Neck CancerOctober 21st 2021
A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.
Clinical Benefit Seen With First-Line Nivolumab Plus Ipilimumab for R/M HNSCC With PD-L1 CPS ≥1 or ≥20October 14th 2021
Patients with recurrent/metastatic head and neck squamous cell carcinoma and a PD-L1 combined positive score of 1 or more and 20 or more experienced a clinical benefit with first-line nivolumab plus ipilimumab compared with the EXTREME regimen.